5-Hydroxytriptolide

Drug Profile

5-Hydroxytriptolide

Alternative Names: 5(R)-5-hydroxytriptolide; Leitengshu; LLDT-8; LLDT-8 cpd; LTS - Shanghai Pharmaceuticals Holding; T8

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Institute of Materia Medica
  • Developer Shanghai Pharmaceuticals Holding
  • Class Anti-inflammatories; Antineoplastics; Antirheumatics; Diterpenes; Herbal medicines
  • Mechanism of Action Immunostimulants; Interferon-gamma expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Rheumatoid arthritis

Most Recent Events

  • 12 Oct 2016 Phase-I/II development is ongoing in China (PO)
  • 01 Jun 2014 Phase-I/II clinical trials in Rheumatoid arthritis in China (PO)
  • 01 Jul 2006 Preclinical trials in Rheumatoid arthritis in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top